Related Experiment Videos
Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
1Department of Cell Biology, Immunology and Experimental Oncology, National Research Centre for Biotechnology (GBF), Braunschweig, Germany. ajschrader@gmx.de
Anti-Cancer Drugs
|June 1, 2000
Abstract:
The therapeutic benefit of adding immunotherapeutic agents such as interferon (IFN)-alpha and interleukin (IL)-2 to established single-agent or combination chemotherapy regimens for the treatment of metastatic melanoma has not been proven. On the contrary, recent studies indicate a significantly higher incidence of severe toxic side effects in patients treated with combined biochemotherapy. This article summarizes recent trials using either chemotherapy alone or chemotherapy plus the administration of IFN-alpha and/or IL-2 to evaluate the benefit of a combined biochemotherapy.